Wire · technology
Insilico Medicine launches industry's first drug discovery and development Benchmark as a Service
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 2 August 2026 · Fusion42 review
Insilico Medicine has launched the industry's first Drug Discovery and Development Benchmark as a Service (BaaS), providing a standardised evaluation framework to measure AI models' real-world performance across drug discovery stages. This service offers independent assessment tailored to frontier AI and foundation models via comprehensive evaluation suites and standard API integration.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it between 31 Jul 2026 and 1 Aug 2026.
◆ ◆ The Wire takeaway
You can now benchmark your AI models against a transparent, standardised metric for drug discovery performance, enabling clearer differentiation and validation in the pharma AI market. This opens a door to prove your model’s real-world impact and gain credibility with pharma partners.
◆ Coverage
2 sources · first reported 31 Jul 2026 · latest 1 Aug 2026
◆ Related on Wire
◆ Topics